NEOGEN CORP (NEOG) Stock Fundamental Analysis

NASDAQ:NEOG • US6404911066

10.97 USD
-0.18 (-1.61%)
Last: Mar 3, 2026, 02:53 PM
Fundamental Rating

3

NEOG gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 184 industry peers in the Health Care Equipment & Supplies industry. NEOG scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. NEOG is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • In the past year NEOG was profitable.
  • NEOG had a positive operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: NEOG reported negative net income in multiple years.
  • Each year in the past 5 years NEOG had a positive operating cash flow.
NEOG Yearly Net Income VS EBIT VS OCF VS FCFNEOG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200M -400M -600M -800M -1B

1.2 Ratios

  • NEOG has a Return On Assets (-17.94%) which is comparable to the rest of the industry.
  • Looking at the Return On Equity, with a value of -28.64%, NEOG is in line with its industry, outperforming 55.98% of the companies in the same industry.
Industry RankSector Rank
ROA -17.94%
ROE -28.64%
ROIC N/A
ROA(3y)-10.81%
ROA(5y)-4.19%
ROE(3y)-17.92%
ROE(5y)-8.21%
ROIC(3y)N/A
ROIC(5y)N/A
NEOG Yearly ROA, ROE, ROICNEOG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20 -40

1.3 Margins

  • NEOG has a worse Gross Margin (45.98%) than 60.87% of its industry peers.
  • In the last couple of years the Gross Margin of NEOG has remained more or less at the same level.
  • NEOG does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 45.98%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.72%
GM growth 5Y0.07%
NEOG Yearly Profit, Operating, Gross MarginsNEOG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100

4

2. Health

2.1 Basic Checks

  • NEOG does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for NEOG remains at a similar level compared to 1 year ago.
  • Compared to 5 years ago, NEOG has more shares outstanding
  • Compared to 1 year ago, NEOG has a worse debt to assets ratio.
NEOG Yearly Shares OutstandingNEOG Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M
NEOG Yearly Total Debt VS Total AssetsNEOG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B

2.2 Solvency

  • NEOG has an Altman-Z score of 1.33. This is a bad value and indicates that NEOG is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of 1.33, NEOG perfoms like the industry average, outperforming 53.80% of the companies in the same industry.
  • NEOG has a Debt/Equity ratio of 0.38. This is a healthy value indicating a solid balance between debt and equity.
  • With a Debt to Equity ratio value of 0.38, NEOG perfoms like the industry average, outperforming 47.28% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.38
Debt/FCF N/A
Altman-Z 1.33
ROIC/WACCN/A
WACC10.16%
NEOG Yearly LT Debt VS Equity VS FCFNEOG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B 2B 3B

2.3 Liquidity

  • NEOG has a Current Ratio of 3.91. This indicates that NEOG is financially healthy and has no problem in meeting its short term obligations.
  • NEOG has a Current ratio of 3.91. This is in the better half of the industry: NEOG outperforms 65.22% of its industry peers.
  • NEOG has a Quick Ratio of 2.80. This indicates that NEOG is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 2.80, NEOG is in the better half of the industry, outperforming 63.04% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.91
Quick Ratio 2.8
NEOG Yearly Current Assets VS Current LiabilitesNEOG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

3

3. Growth

3.1 Past

  • NEOG shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -27.50%.
  • The earnings per share for NEOG have been decreasing by -10.20% on average. This is quite bad
  • The Revenue has decreased by -3.67% in the past year.
  • Measured over the past years, NEOG shows a quite strong growth in Revenue. The Revenue has been growing by 16.43% on average per year.
EPS 1Y (TTM)-27.5%
EPS 3Y-9.82%
EPS 5Y-10.2%
EPS Q2Q%-9.09%
Revenue 1Y (TTM)-3.67%
Revenue growth 3Y19.28%
Revenue growth 5Y16.43%
Sales Q2Q%-2.84%

3.2 Future

  • Based on estimates for the next years, NEOG will show a small growth in Earnings Per Share. The EPS will grow by 7.29% on average per year.
  • The Revenue is expected to decrease by -0.50% on average over the next years.
EPS Next Y-9.33%
EPS Next 2Y1.38%
EPS Next 3Y9.52%
EPS Next 5Y7.29%
Revenue Next Year-4.55%
Revenue Next 2Y-1.49%
Revenue Next 3Y-0.67%
Revenue Next 5Y-0.5%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
NEOG Yearly Revenue VS EstimatesNEOG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M 800M
NEOG Yearly EPS VS EstimatesNEOG Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.2 0.4 0.6

2

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 37.83 indicates a quite expensive valuation of NEOG.
  • Compared to the rest of the industry, the Price/Earnings ratio of NEOG indicates a somewhat cheap valuation: NEOG is cheaper than 71.74% of the companies listed in the same industry.
  • When comparing the Price/Earnings ratio of NEOG to the average of the S&P500 Index (27.13), we can say NEOG is valued slightly more expensively.
  • With a Price/Forward Earnings ratio of 32.35, NEOG can be considered very expensive at the moment.
  • 70.65% of the companies in the same industry are more expensive than NEOG, based on the Price/Forward Earnings ratio.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 28.11, NEOG is valued at the same level.
Industry RankSector Rank
PE 37.83
Fwd PE 32.35
NEOG Price Earnings VS Forward Price EarningsNEOG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of NEOG indicates a somewhat cheap valuation: NEOG is cheaper than 68.48% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 34.8
NEOG Per share dataNEOG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.38%
EPS Next 3Y9.52%

0

5. Dividend

5.1 Amount

  • NEOG does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

NEOGEN CORP

NASDAQ:NEOG (3/3/2026, 2:53:47 PM)

10.97

-0.18 (-1.61%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)01-08
Earnings (Next)04-07
Inst Owners111.94%
Inst Owner Change-16.56%
Ins Owners0.61%
Ins Owner Change24.72%
Market Cap2.39B
Revenue(TTM)880.32M
Net Income(TTM)-602.74M
Analysts78.18
Price Target11.22 (2.28%)
Short Float %4.85%
Short Ratio2.9
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)87.17%
Min EPS beat(2)78.25%
Max EPS beat(2)96.08%
EPS beat(4)2
Avg EPS beat(4)32.2%
Min EPS beat(4)-34.64%
Max EPS beat(4)96.08%
EPS beat(8)3
Avg EPS beat(8)11.3%
EPS beat(12)5
Avg EPS beat(12)119.18%
EPS beat(16)6
Avg EPS beat(16)37.27%
Revenue beat(2)2
Avg Revenue beat(2)3.22%
Min Revenue beat(2)0.46%
Max Revenue beat(2)5.99%
Revenue beat(4)2
Avg Revenue beat(4)0.6%
Min Revenue beat(4)-3.66%
Max Revenue beat(4)5.99%
Revenue beat(8)3
Avg Revenue beat(8)0.18%
Revenue beat(12)4
Avg Revenue beat(12)-0.24%
Revenue beat(16)4
Avg Revenue beat(16)-0.78%
PT rev (1m)0%
PT rev (3m)44.26%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-20.69%
EPS NY rev (1m)0%
EPS NY rev (3m)22.22%
Revenue NQ rev (1m)-0.44%
Revenue NQ rev (3m)2.17%
Revenue NY rev (1m)-0.05%
Revenue NY rev (3m)3.31%
Valuation
Industry RankSector Rank
PE 37.83
Fwd PE 32.35
P/S 2.71
P/FCF N/A
P/OCF 36.05
P/B 1.13
P/tB N/A
EV/EBITDA 34.8
EPS(TTM)0.29
EY2.64%
EPS(NY)0.34
Fwd EY3.09%
FCF(TTM)-0.08
FCFYN/A
OCF(TTM)0.3
OCFY2.77%
SpS4.05
BVpS9.67
TBVpS-1.38
PEG (NY)N/A
PEG (5Y)N/A
Graham Number7.95
Profitability
Industry RankSector Rank
ROA -17.94%
ROE -28.64%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 45.98%
FCFM N/A
ROA(3y)-10.81%
ROA(5y)-4.19%
ROE(3y)-17.92%
ROE(5y)-8.21%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.72%
GM growth 5Y0.07%
F-Score4
Asset Turnover0.26
Health
Industry RankSector Rank
Debt/Equity 0.38
Debt/FCF N/A
Debt/EBITDA 8.98
Cap/Depr 71.99%
Cap/Sales 9.62%
Interest Coverage N/A
Cash Conversion 74.97%
Profit Quality N/A
Current Ratio 3.91
Quick Ratio 2.8
Altman-Z 1.33
F-Score4
WACC10.16%
ROIC/WACCN/A
Cap/Depr(3y)85.8%
Cap/Depr(5y)97.5%
Cap/Sales(3y)10.58%
Cap/Sales(5y)8.42%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-27.5%
EPS 3Y-9.82%
EPS 5Y-10.2%
EPS Q2Q%-9.09%
EPS Next Y-9.33%
EPS Next 2Y1.38%
EPS Next 3Y9.52%
EPS Next 5Y7.29%
Revenue 1Y (TTM)-3.67%
Revenue growth 3Y19.28%
Revenue growth 5Y16.43%
Sales Q2Q%-2.84%
Revenue Next Year-4.55%
Revenue Next 2Y-1.49%
Revenue Next 3Y-0.67%
Revenue Next 5Y-0.5%
EBIT growth 1Y-193.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year138.34%
EBIT Next 3Y34.61%
EBIT Next 5Y20.01%
FCF growth 1Y-209.2%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-41.22%
OCF growth 3Y-5.05%
OCF growth 5Y-7.47%

NEOGEN CORP / NEOG FAQ

What is the fundamental rating for NEOG stock?

ChartMill assigns a fundamental rating of 3 / 10 to NEOG.


What is the valuation status of NEOGEN CORP (NEOG) stock?

ChartMill assigns a valuation rating of 2 / 10 to NEOGEN CORP (NEOG). This can be considered as Overvalued.


How profitable is NEOGEN CORP (NEOG) stock?

NEOGEN CORP (NEOG) has a profitability rating of 2 / 10.


What is the financial health of NEOGEN CORP (NEOG) stock?

The financial health rating of NEOGEN CORP (NEOG) is 4 / 10.


What is the expected EPS growth for NEOGEN CORP (NEOG) stock?

The Earnings per Share (EPS) of NEOGEN CORP (NEOG) is expected to decline by -9.33% in the next year.